1. Volume 147, Issue 6, Pages 1327-1337.e3 (December 2014)
Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis: A Randomized, Controlled Trial 
Radha K. Dhiman, Baldev Rana, Swastik Agrawal, Ashish Garg, Madhu Chopra, Kiran K. Thumburu, Amit Khattri, Samir Malhotra, Ajay Duseja, Yogesh K. Chawla 
Gastroenterology 
Volume 147, Issue 6, Pages e3 (December 2014)
DOI: /j.gastro
Copyright © 2014 AGA Institute Terms and Conditions

2. Figure 1 CONSORT diagram. ITT, intent to treat.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2014 AGA Institute Terms and Conditions

3. Figure 2
Hazard of breakthrough episode of hepatic encephalopathy in the probiotic and placebo groups.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2014 AGA Institute Terms and Conditions

4. Figure 3
Hazard of hospitalization in the probiotic and placebo groups.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2014 AGA Institute Terms and Conditions

5. Supplementary Figure 1
Hazard of death in the probiotic and placebo groups.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2014 AGA Institute Terms and Conditions

6. Supplementary Figure 2
CTP scores at baseline, and at 12 and 24 weeks in the probiotic and placebo groups.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2014 AGA Institute Terms and Conditions

7. Supplementary Figure 3
MELD scores at baseline, and at 12 and 24 weeks in the probiotic and placebo groups.
Gastroenterology  , e3DOI: ( /j.gastro )
Copyright © 2014 AGA Institute Terms and Conditions